Biotech Values

[rfj1862]

I took "literally waiting for the approval letter right now" to mean that they passed inspection.

It's really unfair that they don't broadcast the breakout sessions; willing to be someone asked that question.

The key in terms of acquisition is whether there are any structural changes that will need to be made to make room for the acquired product. The reason I say MDCO is that they are already hitting *exactly* the right target audiences, have a field force in place, and have long-term relationships with the very physician population that will be buying Dyloject and the ketamine product. Which I wish they would name so I can stop referring to it as the "ketamine product."